Most cited papers from Incyte (United States)

Incyte (United States)

What are the most cited papers from Incyte (United States)?

The most cited paper from Incyte (United States) is "Genome sequence of the Brown Norway rat yields insights into mammalian evolution" (Richard A. Gibbs et al., 2004), with 2,224 citations. Next come "A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis" (2,106) and "Systematic variation in gene expression patterns in human cancer cell lines" (2,103).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 318 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Genome sequence of the Brown Norway rat yields insights into mammalian evolution Richard A. Gibbs et al. · Nature Open access248 authors	Apr 2004	2,224
2	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis Srđan Verstovšek et al. · New England Journal of Medicine Open access	29 Feb 2012	2,106
3	Systematic variation in gene expression patterns in human cancer cell lines Douglas T. Ross, Uwe Scherf, Michael B. Eisen et al. · Nature Genetics	Mar 2000	2,103
4	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis Claire N. Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine Open access	29 Feb 2012	1,830
5	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology Open access	20 Mar 2020	1,634
6	CCR2 modulates inflammatory and metabolic effects of high-fat feeding Stuart Phillip Weisberg, Deborah Hunter, Reid Huber et al. · Journal of Clinical Investigation Open access	8 Dec 2005	1,485
7	Distinctive gene expression patterns in human mammary epithelial cells and breast cancers Charles M. Perou, Stefanie S. Jeffrey, Matt van de Rijn et al. · Proceedings of the National Academy of Sciences Open access	3 Aug 1999	1,419
8	Control of apoptosis by p53 Jordan S. Fridman, Scott W. Lowe · Oncogene	8 Dec 2003	1,413
9	Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension Inês Barroso, Mark Gurnell, Vivion Crowley et al. · Nature	Dec 1999	1,380
10	A comparison of selected mRNA and protein abundances in human liver Leigh Anderson, Jeff Seilhamer · Electrophoresis	1997	1,270
11	Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa et al. · New England Journal of Medicine Open access	15 Sep 2010	1,176
12	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Georgina Venetia Long, Reinhard Dummer, Omid Hamid et al. · The Lancet Oncology	17 Jun 2019	991
13	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Hans-Guido Wendel, Elisa de Stanchina, Jordan S. Fridman et al. · Nature	Mar 2004	958
14	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera Alessandro Maria Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer et al. · New England Journal of Medicine Open access	28 Jan 2015	893
15	Iontophoretic drug delivery Yogeshvar N. Kalia, Aarti Naik, James L. Garrison et al. · Advanced Drug Delivery Reviews ReviewOpen access	22 Dec 2003	860
16	Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis Christopher E.M. Griffiths, Bruce E Strober, Peter van de Kerkhof et al. · New England Journal of Medicine	13 Jan 2010	858
17	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Alfonso Quintás‐Cardama et al. · Blood Open access	3 Feb 2010	844
18	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Alexander Edward Dela Cruz Drilon et al. · Cancer Discovery Open access	9 Feb 2017	836
19	Microarrays: biotechnology's discovery platform for functional genomics Mark Schena, Renu A. Heller, Thomas P Theriault et al. · Trends in biotechnology ReviewOpen access	Jul 1998	796
20	Genome of the Bacterium Streptococcus pneumoniae Strain R6 JoAnn Hoskins et al. · Journal of Bacteriology Open access	Oct 2001	738
21	The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway Richard M. Lawn, David P. Wade, Michael R. Garvin et al. · Journal of Clinical Investigation Open access	15 Oct 1999	729
22	Regulation of zygotic gene expression in Drosophila primordial germ cells Mark Van Doren, Anne Williamson, Ruth Lehmann · Current Biology Open access	Feb 1998	702
23	Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires Scott Southwood, John Sidney, Akihiro Kondo et al. · The Journal of Immunology	Apr 1998	670
24	NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018 Alexander Dimitrios Colevas et al. · Journal of the National Comprehensive Cancer Network Open access	May 2018	642
25	Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors Jason J. Luke, Jeffrey M. Lemons, Theodore G Karrison et al. · Journal of Clinical Oncology Open access	13 Feb 2018	597
26	Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome Vanessa S. Marsden, Liam J. O’Connor, Lorraine Ann O’Reilly et al. · Nature	25 Sep 2002	587
27	Genomic Analysis of a Nutrient Response in Arabidopsis Reveals Diverse Expression Patterns and Novel Metabolic and Potential Regulatory Genes Induced by Nitrate Rongchen Wang, Karl Guegler, Samuel T. LaBrie et al. · The Plant Cell Open access	Aug 2000	577
28	Paucity of Genes on the Drosophila X Chromosome Showing Male-Biased Expression Michael J Parisi, Rachel Nuttall, Daniel Q. Naiman et al. · Science Open access	30 Jan 2003	574
29	Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A Claus Storgaard Sørensen, Randi G. Syljuåsen, Jacob Falck et al. · Cancer Cell Open access	Mar 2003	572
30	Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Xiangdong Liu et al. · Blood Open access	3 Mar 2010	564
31	Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment Stefani Spranger, Holly K. Koblish, Brendan L. Horton et al. · Journal for ImmunoTherapy of Cancer Open access	2014	560
32	Diffusion of Macromolecules and Virus-Like Particles in Human Cervical Mucus Stuart S. Olmsted, Janet L. Padgett, Ashley I. Yudin et al. · Biophysical Journal Open access	Oct 2001	550
33	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease Robert Zeiser, Nicola Polverelli, Ron Ram et al. · New England Journal of Medicine Open access	14 Jul 2021	532
34	Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis on behalf of the COMFORT-II Investigators, Claire N. Harrison, Alessandro Maria Vannucchi et al. · Leukemia Open access	23 May 2016	521
35	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer Ryan Bruce Corcoran, Chloe Evelyn Atreya, Gerald Steven Falchook et al. · Journal of Clinical Oncology Open access	22 Sep 2015	519
36	LINEAR MODELING OF mRNA EXPRESSION LEVELS DURING CNS DEVELOPMENT AND INJURY Patrik D’haeseleer, Xi Wen, Stefanie Fuhrman et al. Conference paper	Dec 1998	504
37	Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 Jordan S. Fridman et al. · The Journal of Immunology Open access	7 Apr 2010	467
38	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial for the COMFORT-I investigators et al. · Journal of Hematology & Oncology Open access	22 Feb 2017	436
39	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis Francisco Cervantes, Alessandro Maria Vannucchi, Jean‐Jacques Kiladjian et al. · Blood Open access	30 Oct 2013	430
40	Cholesterol and matrisome pathways dysregulated in astrocytes and microglia Julia TCW et al. · Cell Open access	Jun 2022	427
41	Expression Profile Analysis of the Low-Oxygen Response in Arabidopsis Root Cultures[W] Erik Jan Klok, Iain W. Wilson, Dale Wilson et al. · The Plant Cell Open access	Oct 2002	425
42	CCL2 Mediates Cross-talk between Cancer Cells and Stromal Fibroblasts That Regulates Breast Cancer Stem Cells Akihiro Tsuyada, Amy Yin Man Chow, Jun Wu et al. · Cancer Research Open access	3 Apr 2012	411
43	Targeting the checkpoint kinases: chemosensitization versus chemoprotection Bin‐Bing S. Zhou, Jiří Bártek · Nature reviews. Cancer Review	Mar 2004	391
44	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer Bin-Bing Zhou et al. · Cancer Cell Open access	Jul 2006	375
45	Medicinal Benefits of Green Tea: Part I. Review of Noncancer Health Benefits Raymond Cooper, D. James Morré, Dorothy M. Morré · The Journal of Alternative and Complementary Medicine	Jun 2005	359
46	The promise and challenges of immune agonist antibody development in cancer Patrick A. Mayes, Kenneth W. Hance, Axel Hoos · Nature Reviews Drug Discovery Review	15 Jun 2018	357
47	Cdk1/Erk2- and Plk1-Dependent Phosphorylation of a Centrosome Protein, Cep55, Is Required for Its Recruitment to Midbody and Cytokinesis Megan Fabbro, Bin‐Bing S. Zhou, Mikiko Takahashi et al. · Developmental Cell Open access	Oct 2005	350
48	A critical analysis of the accuracy, reproducibility, and clinical utility of histologic endometrial dating in fertile women Michael J. Murray, William R. Meyer, Richard J. Zaino et al. · Fertility and Sterility Open access	May 2004	349
49	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance Vivek Verma et al. · Nature Immunology Open access	29 Jul 2019	341
50	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I Srđan Verstovšek et al. · Haematologica Open access	23 Jan 2015	334

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.